Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

110 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-01

Study Completion Date

2022-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Autoimmune encephalitis and paraneoplastic neurological syndromes are rare diseases caused by an abnormal immune response toward the nervous system. This can lead to life-threatening symptoms, but is in many cases treatable if a swift and correct diagnosis is made. Antibodies targeting neuronal proteins (i.e. "neuronal antibodies") can be detected in serum or cerebrospinal fluid (CSF) in about half of the patients suffering from these conditions. Although an important part of the diagnostical process of these conditions, diagnosis cannot be made only based on a positive antibody test, but the clinical findings have to be compatible as well. As these conditions are so rare, clinicians might struggle to interpret antibody test results.

In this study the investigators aim to estimate the incidence rate of autoimmune encephalitides and paraneoplastic neurological syndromes in the Uppsala-Örebro health care region in Sweden between the years 2015 and 2019. Medical records from patients belonging to the Uppsala-Örebro health care region (a region in the middle of Sweden with a population of approximately 2.1 million), that tested positive for any neuronal antibody in serum or CSF will be studied to obtain clinical, laboratory and radiological data. This data will be used to ascertain if diagnostic criteria are fulfilled as well as to describe clinical characteristics and identifying possible comorbidities.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis Collection

NCT05198661

Paraneoplastic Neurological Syndromes or Autoimmune Encephalitis

RECRUITING NA

Biomarkers in Autoimmune Disease of Nervous System

NCT06502015

Autoimmune Diseases of the Nervous System Neuromyelitis Optica Spectrum Disorder Multiple Sclerosis +8 more

RECRUITING

Serum Auto-Antibodies in Neurological Diseases

NCT00704626

Multiple Sclerosis Myasthenia Gravis Transverse Myelitis

ENROLLING_BY_INVITATION

Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity

NCT06169150

Nervous System Disease Immune System Disease

RECRUITING

Neuropathy and Anti-GFAP Antibodies

NCT05742087

Neurological Diseases or Conditions Neurological Diseases Associated to Anti GFAP Antibodies

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Methods:

1. Identification of extended cohort:

The extended cohort consists of all patients in Sweden tested for any neuronal antibody in serum or CSF between 2015 and 2019. Patients will be identified by the only five laboratories that perform tests for neuronal antibodies in Sweden. The following neuronal antibodies will be included: AMPA 1 (Anti-Glutamate Receptor 1), AMPA 2 (Anti-Glutamate Receptor 2), Amphiphysin, CARP VIII (Carbonic Anhydrase-Related Protein VIII), CASPR2 (Contactin-associated protein-like 2), CV2/CRMP5 (collapsin response mediator protein 5), DPPX (dipeptidyl-peptidase-like protein 6), GABA B (γ-Aminobutyric acid-B receptor), GAD65 (glutamic acid decarboxylase) (\>2000 IU/ml by ELISA in serum, or detected in CSF), glycine receptor, Homer 3, Hu (antineuronal nuclear antibody-type 1, ANNA-1), IgLON5 (immunoglobulin-like cell adhesion molecule 5 ), ITPR1 (inositol 1,4,5-trisphophate receptor type 1), LGI-1 (Leucine-rich glioma-inactivated 1), Ma2/Ta, NMDAR (anti-N-methyl-D-aspartate receptor), PCA-2 (Purkinje cell cytoplasmic antibody type 2), Tr (Trotter), Ri, SOX1(SRY-Box Transcription Factor 1), VGCC (Voltage-gated calcium channels), Yo, Zic4 (Zinc finger protein).
2. Identification of geographical region:

Patients testing positive for any neuronal antibody in serum or CSF will be stratified according to which Swedish health care region that requested the test. Patients whose tests where requested by health care providers in the Uppsala-Örebro health care region (consisting of 7 smaller health care regions with a total population of approximately 2.1 million) will be selected.
3. Core cohort:

Patients with a positive test result that belong to the Uppsala-Örebro health care region will be contacted and asked to participate in the study. Written informed consent must be signed to be included in the core cohort. If the patient is deceased, consent will be presumed.
4. Case ascertainment:

Medical records from patients included in the core cohort will be reviewed to obtain clinical, laboratory and radiological data. Ascertainment of a case is defined as the patient either fulfilling criteria of: 1) "definite PNS" according to Graus et. al 2021 or 2) "definite autoimmune limbic encephalitis" according to Graus et al. 2016 or 3) "definite anti-NMDA receptor encephalitis" according to Graus et al. 2016.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autoimmune Encephalitis Paraneoplastic Neurological Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Extended Cohort: Patients tested for any neuronal antibody in the Swedish population

All patients tested for any neuronal antibody in serum or CSF between 2015 and 2019 in Sweden.

Description and analysis

Intervention Type OTHER

Collection of laboratory data.

Core Cohort: Patients with a positive neuronal antibody test belonging to the Uppsala-Örebro region

All patients belonging to the Uppsala-Örebro health care region (a region in the middle of Sweden with a population of approximately 2.1 million), that tested positive for any neuronal antibody in serum or cerebrospinal fluid between 2015-2019.

Description and analysis

Intervention Type OTHER

Collection of clinical, laboratory and radiological data from medical records.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Description and analysis

Collection of clinical, laboratory and radiological data from medical records.

Intervention Type OTHER

Description and analysis

Collection of laboratory data.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All ages, both sexes.
* Neuronal antibody (AMPA 1, AMPA 2, Amphiphysin, CARP VIII, CASPR2, CV2/CRMP5, DPPX, GABA B, GAD65(\>2000 IU/ml by ELISA in serum, or detected in CSF), glycine receptor, Homer 3, Hu, IgLON5, ITPR1, LGI-1, Ma2/Ta, NMDAR, PCA-2, Tr, Ri, SOX1, VGCC, Yo, Zic4), detected in serum or cerebrospinal fluid between 2015-2019
* Antibody test was requested by a health care facility in the Uppsala-Örebro health care region
* Signed informed consent. If the participant is deceased consent will be presumed

Exclusion Criteria

* Incomplete personal data or social security number making it impossible to identify and/or contact the patient to get written consent
* Informed consent not signed. If the participant is deceased consent will be presumed

Eligible Sex

ALL

Accepts Healthy Volunteers

No